J Korean Acad Nurs.  2014 Dec;44(6):735-742. 10.4040/jkan.2014.44.6.735.

Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy

• Kim HY
• Kang JH
• Youn HJ
• So HS
• Song CE
• Chae SY
• Jung SH
• Kim SR
• Kim JY

• KMID: 2129564
• DOI: http://doi.org/10.4040/jkan.2014.44.6.735

Abstract

PURPOSE
This study was performed to assess the reliability and validity of the Korean version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-induced peripheral neuropathy 20 items (EORTC QLQ-CIPN20) in patients receiving neurotoxic chemotherapy.
METHODS
A convenience sample of 249 Korean cancer patients, previously or currently, being treated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire. Collected data were analyzed using SPSS 21.0 and AMOS 21.0. Construct validity, known-group validity, concurrent validity, and internal consistency reliability of the Korean version of the QLQ-CIPN20 were evaluated.
RESULTS
Factor analysis confirmed 3 dimensions of CIPN: sensory, motor, and autonomic. The factor loadings of the 20 items on the 3 subscales ranged from .38 to .85. The 3 subscale-model was validated by confirmatory factor analysis (GFI=.90, AGFI=.86, RMSR=.05, NFI=.87, and CFI=.94), and concurrent validity was demonstrated with the EORTC QLQ-C30. Furthermore, the QLQ-CIPN20 established known-group validity. The Cronbach's alpha coefficients for internal consistency of the subscales ranged from .73 to .89.
CONCLUSION
The Korean version of the EORTC QLQ-CIPN20 showed satisfactory construct, concurrent, and known-group validity, as well as internal reliability.

Keyword

Validity; Reliability; Chemotherapy; Peripheral neuropathies

MeSH Terms

Adult
Aged
Antineoplastic Agents/*adverse effects/therapeutic use
Asian Continental Ancestry Group
Female
Health Status
Humans
Male
Middle Aged
Neoplasms/drug therapy
Peripheral Nervous System Diseases/*etiology
Pilot Projects
*Quality of Life
Questionnaires
Republic of Korea
Research Design
*Translating
Antineoplastic Agents

Reference

References

1. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: Differential diagnosis and management. American Family Physician. 2010; 81(7):887–892.

2. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005; 41(8):1135–1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012.

3. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. The Journal of Supportive Oncology. 2006; 4(8):398–399.

4. Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncology. 2010; 11(11):1086–1095. http://dx.doi.org/10.1016/s1470-2045(10)70068-1.

5. Kautio AL, Haanpää M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Supportive Care in Cancer. 2011; 19(12):1991–1996. http://dx.doi.org/10.1007/s00520-010-1043-2.

6. Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum. 2010; 37(6):758–764. http://dx.doi.org/10.1188/10.onf.758-764.

7. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing. 2011; 15(2):182–188. http://dx.doi.org/10.1188/11.cjon.182-188.

8. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2007; 11(6):901–913. http://dx.doi.org/10.1188/07.cjon.901-913.

9. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Beren-son J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006; 24(19):3113–3120. http://dx.doi.org/10.1200/jco.2005.04.7779.

10. Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy: A systematic review of psychometric properties. Journal of the Peripheral Nervous System. 2010; 15(4):314–325. http://dx.doi.org/10.1111/j.1529-8027.2010.00292.x.

11. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 2000; 11(5):509–513.

12. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing. 2007; 11(3):361–376. http://dx.doi.org/10.1188/07.cjon.361-376.

13. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology. 2013; 24(2):454–462. http://dx.doi.org/10.1093/annonc/mds329.

14. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 2011; 19(6):833–841. http://dx.doi.org/10.1007/s00520-010-0911-0.

15. Kim HY, Kang JH, Song CE, Youn HJ. Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing. 2013; 13(4):222–230. http://dx.doi.org/10.5388/aon.2013.13.4.222.

16. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. Journal of Clinical Oncology. 2013; 31(21):2699–2707. http://dx.doi.org/10.1200/jco.2013.49.1514.

17. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2011; 11(3):254–262. http://dx.doi.org/10.5388/jkon.2011.11.3.254.

18. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2010; 10(2):231–239. http://dx.doi.org/10.5388/jkon.2010.10.2.231.

19. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. EORTC quality of life group translation procedure. 3rd ed. Brussels, BE: EORTC Quality of Life Group;2009.

20. Tabachnick BG, Fidell LS. Using multivariate statistics. 3rd ed. New York, NY: Harper Collins Publishers;1996.

21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, BE: EORTC Quality of Life Group;2001.

22. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research. 2004; 13(4):863–868.

23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993; 85(5):365–376.

24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982; 5(6):649–655.

25. Kim GS. Analysis structural equation modeling. Seoul: Hannarae Publishing Co.;2007.

26. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York, NY: McGraw-Hill;1994.

27. Kim EJ. Accessing factor structure and construct validity of the successful aging inventory. Journal of Korean Academy of Nursing. 2013; 43(4):568–578. http://dx.doi.org/10.4040/jkan.2013.43.4.568.

28. Park HA. Problems and issues in developing measurement scales in nursing. Journal of Nursing Query. 2005; 14(1):46–72.

29. Kim SH, Jo MW, Lee SI. Psychometric properties of the Korean short form-36 health survey version 2 for assessing the general population. Asian Nursing Research. 2013; 7(2):61–66.

30. Lee EH, Moon S, Cho SY, Oh YT, Chun M, Kim SH, et al. Psychometric evaluation of a need scale for cancer patients undergoing follow-up care. Journal of Korean Academy of Nursing. 2010; 40(4):551–560. http://dx.doi.org/10.4040/jkan.2010.40.4.551.